Top Markets
#1 MON MON +2,760.08%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +52.36%
#4 eCash eCash +37.30%
#5 PinGo PinGo +24.63%
#6 Siren Siren +24.28%
#7 Collector Crypt Collector Crypt +23.96%
#8 SAFEcoin SAFEcoin +19.72%
#9 Janction Janction +19.66%
#10 Velvet Velvet +14.95%
Coin of the day
MON MON
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Classement en actions #13334
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Prix de l'action
$0.30840035
Capitalisation boursière
$94.37M
Changement (1 jour)
0.00%
Changement (1 an)
-34.60%
Pays
FR
Échange Sensorion SA (ALSEN)

Catégorie

Healthcare
Ratio P/B pour Sensorion SA (ALSEN)
Ratio P/B au July 2026 TTM : 1.60
Selon les derniers rapports financiers et le cours de l'action de Sensorion SA, le ratio cours/valeur comptable actuel (TTM) est 1.60. À la fin de 2023, le ratio P/B était de 1.72.
Historique du ratio P/B pour Sensorion SA de 2011 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
2026 (TTM) 1.60 -36.00%
2024 2.50 45.20%
2023 1.72 27.66%
2022 1.35 -61.30%
2021 3.49 123.40%
2020 1.56 30.96%
2019 1.19 -63.54%
2018 3.27 -14.29%
2017 3.82 0.09%
2016 3.81 33.08%
2015 2.87 -106.25%
2014 -45.83 271.31%
2013 -12.34 -102.18%
2012 567.35 254.28%
2011 160.14 0.00%
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 6.8826 330.16%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.5189 307.43%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.0637 28.98%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.5808 186.30%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.7629 385.18%
NL